content:fires

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
content:fires [2020/02/14 17:38]
icna [Treatment]
content:fires [2020/02/14 17:47] (current)
icna [Treatment]
Line 47: Line 47:
   * The efficacy of ketogenic diet as an alternative to pharmacotherapy in FIRES has been reported with favourable outcomes[(:​cite:​20813015>​{{pubmed>​short:​20813015}})][(:​cite:​19191829>​{{pubmed>​short:​19191829}})]. There are no randomized controlled trials available on the use of the ketogenic diet in status epilepticus[(:​ref:​todo)].   * The efficacy of ketogenic diet as an alternative to pharmacotherapy in FIRES has been reported with favourable outcomes[(:​cite:​20813015>​{{pubmed>​short:​20813015}})][(:​cite:​19191829>​{{pubmed>​short:​19191829}})]. There are no randomized controlled trials available on the use of the ketogenic diet in status epilepticus[(:​ref:​todo)].
   * Deep brain stimulation of the centromedian thalamic nuclei (CMN-DBS) has been reported in some cases with where generalised seizures have been abolished but did not have a lasting effect on focal seizures burden[(:​cite:​31446001>​{{pubmed>​short:​31446001}})]   * Deep brain stimulation of the centromedian thalamic nuclei (CMN-DBS) has been reported in some cases with where generalised seizures have been abolished but did not have a lasting effect on focal seizures burden[(:​cite:​31446001>​{{pubmed>​short:​31446001}})]
-  * There are also case reports on the use of Anakinra (a recombinant version of the human interleukin-1 receptor antagonist) in FIRES but with variable outcomes[(:​cite:​31446001>​{{pubmed>​short:​31446001}})] ​+  * There are also case reports on the use of [[Anakinra]] (a recombinant version of the human interleukin-1 receptor antagonist) in FIRES but with variable outcomes[(:​cite:​31446001>​{{pubmed>​short:​31446001}})] ​
   * Gofshteyn et al.(2017) reported an open label case series where cannabadiol (Epidiolex, GW Pharma) was used alongside other anti-seizure medications on emergency or expanded investigational protocols in either the acute or chronic phase of illness and showed improvement in seizure frequency and duration[(:​cite:​27655472>​{{pubmed>​short:​27655472}})]   * Gofshteyn et al.(2017) reported an open label case series where cannabadiol (Epidiolex, GW Pharma) was used alongside other anti-seizure medications on emergency or expanded investigational protocols in either the acute or chronic phase of illness and showed improvement in seizure frequency and duration[(:​cite:​27655472>​{{pubmed>​short:​27655472}})]
 ==== References ==== ==== References ====
  • content/fires.txt
  • Last modified: 3 months ago
  • by icna